1356 studies found for:    Recruiting | cancer | United States, Texas
Show Display Options
Rank Status Study
21 Recruiting Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: abiraterone;   Drug: prednisone
22 Recruiting Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Large Cell Lung Cancer;   Metastatic Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: veliparib;   Other: placebo;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
23 Recruiting Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: mitoxantrone;   Drug: prednisone
24 Recruiting Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: veliparib;   Other: hydrocortisone/placebo;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: 3-dimensional conformal radiation therapy
25 Recruiting A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Interventions: Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone
26 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: laboratory biomarker analysis
27 Recruiting S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
Interventions: Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
28 Recruiting Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Cancer of Ovary;   Cancer of the Ovary;   Ovary Neoplasms;   Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
29 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Transitional Cell Carcinoma of the Bladder;   Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
30 Recruiting Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Paget Disease of the Breast;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docosahexaenoic acid;   Other: placebo;   Other: laboratory biomarker analysis
31 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin
32 Recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant;   Drug: anastrozole
33 Recruiting Observation in Patients With Early-Stage Vulvar Cancer Following Surgery and/or Radiation Therapy
Conditions: Long-term Effects Secondary to Cancer Therapy in Adults;   Squamous Cell Carcinoma of the Vulva;   Stage I Vulvar Cancer;   Stage II Vulvar Cancer;   Stage III Vulvar Cancer
Interventions: Other: clinical observation;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic lymphadenectomy;   Radiation: selective external radiation therapy
34 Recruiting Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Conditions: Glioblastoma Multiforme;   Squamous Cell Carcinoma of Head and Neck;   Prostate Cancer;   Ewing's Osteosarcoma;   Chronic Lymphocytic Leukemia;   Neoplasm Metastasis
Intervention: Drug: CC-115
35 Recruiting Dasatinib in Treating Patients With Solid Tumor or Lymphoma That Are Metastatic or Cannot Be Removed By Surgery
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: dasatinib;   Other: pharmacological study
36 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Intraductal Papillary Mucinous Neoplasm of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: erlotinib hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: capecitabine;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
37 Recruiting Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Conditions: Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Drug: doxorubicin hydrochloride;   Procedure: therapeutic conventional surgery;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: carboplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy
38 Recruiting Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Conditions: Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
39 Recruiting A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Conditions: Cancer;   Cataract;   Low Bone Mineral Density;   Osteopenia;   Osteoporosis;   Prostate Cancer
Interventions: Biological: Denosumab;   Biological: Placebo
40 Recruiting Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
Conditions: Brain and Central Nervous System Tumors;   Cognitive/Functional Effects;   Fatigue;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil;   Other: placebo

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years